サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1414387

メラノーマ治療薬の世界市場レポート 2024年

Melanoma Therapeutics Global Market Report 2024
出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2～10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
メラノーマ治療薬の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
  • 全表示
  • 概要
  • 目次
概要

メラノーマ治療薬の市場規模は近年急速に拡大しています。2023年の36億7,000万米ドルから2024年には41億米ドルへと、CAGR11.6％で拡大します。過去の期間に観察された成長は、治療ガイドラインの変化、意識の高まりと早期発見への取り組み、規制当局の承認、臨床試験への参加、さらに手術技術の進歩に起因しています。

高齢化人口の増加は、今後数年間のメラノーマ治療薬市場の成長を促進すると予想されます。高齢化社会は、人口に占める65歳以上の高齢者の割合が高くなることを特徴とし、メラノーマの有病率が増加します。メラノーマ治療薬は、年齢が進むにつれて一般的になるこの皮膚がんへの対応において、重要な役割を果たしています。2022年10月、世界保健機関（WHO）は、60歳以上の世界人口が2020年の10億人から2022年には14億人に増加したと報告しました。60歳以上の人口は2050年までに全世界で倍増し、21億人に達すると予測されています。さらに、80歳以上の高齢者数は2050年までに3倍となり、4億2,600万人に達すると予想されています。したがって、高齢化の進展はメラノーマ治療薬市場の重要な促進要因です。

2023年のメラノーマ治療薬市場で最大の地域は北米です。メラノーマ治療薬市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東、アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界市場規模と成長

  • 世界のメラノーマ治療薬市場の促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界のメラノーマ治療薬市場規模実績と成長、2018～2023年
  • 世界のメラノーマ治療薬市場規模と成長予測、2023～2028年、2033年

第6章 市場セグメンテーション

  • 世界のメラノーマ治療薬市場、薬剤タイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • モノクローナル抗体
  • 低分子阻害剤
  • その他
  • 世界のメラノーマ治療薬市場、治療法別セグメンテーション：、実績と予測、2018～2023年、2023～2028年、2033年
  • 手術
  • 放射線治療
  • 免疫療法
  • 標的療法
  • 化学療法
  • 世界のメラノーマ治療薬市場、投与経路別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 経口
  • 注射
  • 世界のメラノーマ治療薬市場、がんタイプ別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 表在性メラノーマ
  • 結節性メラノーマ
  • レンチニョ悪性メラノーマ
  • 末端黒子メラノーマ
  • アメラノーマ性メラノーマ
  • その他
  • 世界のメラノーマ治療薬市場、診断別セグメンテーション、実績と予測、2018～2023年、2023～2028年、2033年
  • 皮膚鏡検査
  • 中腸リンパ節生検
  • 血液検査
  • X線
  • 超音波
  • CTスキャン

第7章 地域と国の分析

  • 世界のメラノーマ治療薬市場、地域別、実績と予測、2018～2023年、2023～2028年、2033年
  • 世界のメラノーマ治療薬市場、国別、実績と予測、2018～2023年、2023～2028年、2033年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • メラノーマ治療薬市場の競合情勢
  • メラノーマ治療薬市場の企業プロファイル
    • AstraZeneca plc
    • Bristol-Myers Squibb Co.
    • Eli Lilly and Company
    • Merck &Co. Inc.
    • Novartis AG

第31章 競合ベンチマーキング

第32章 競合ダッシュボード

第33章 主要な合併と買収

第34章 将来の展望と潜在性分析

第35章 付録

目次
Product Code: r11897

“Melanoma Therapeutics Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on melanoma therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for melanoma therapeutics? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The melanoma therapeutics market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug Type: Monoclonal Antibodies; Small Molecule Inhibitors; Other Drug Types
  • 2) By Therapy: Surgery; Radiation Therapy; Immunotherapy; Targeted Therapy; Chemotherapy
  • 3) By Route of administration: Oral; Injectable
  • 4) By Cancer Type: Superficial Spreading Melanoma; Nodular Melanoma; Lentigo Maligna Melanoma; Acral Lentiginous Melanoma; Amelanotic Melanoma; Other Cancer Types
  • 5) By Diagnosis: Dermatoscopy; Sentinel Lymph Node Biopsy; Blood Test; X-ray; Ultrasound; CT Scan
  • Companies Mentioned: AstraZeneca plc; Bristol-Myers Squibb Co.; Eli Lilly and Company; Merck & Co. Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Melanoma therapeutics refer to treatment procedures employed for addressing melanoma, a form of skin cancer that originates in the melanocytes. These therapies operate by targeting abnormal cells, either by directly eliminating them or by impeding their growth and multiplication.

The primary categories of melanoma therapeutic drugs include monoclonal antibodies, small-molecule inhibitors, and others. Monoclonal antibodies are synthetic therapeutic proteins designed to bind to specific targets, such as antigens present in cancer cells, and are produced in laboratory settings. Various treatment modalities are encompassed, such as surgery, radiation therapy, immunotherapy, targeted therapy, and chemotherapy, and these therapies are administered through various routes, including oral and injectable methods. Melanoma is categorized into different types, including superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma, acral lentiginous melanoma, amelanotic melanoma, and others. Diagnosis involves techniques such as dermatoscopy, sentinel lymph node biopsy, blood tests, x-rays, ultrasound, and CT scans.

The melanoma therapeutics market research report is one of a series of new reports from The Business Research Company that provides melanoma therapeutics market statistics, including melanoma therapeutics industry global market size, regional shares, competitors with a melanoma therapeutics market share, detailed melanoma therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the melanoma therapeutics industry. This melanoma therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The melanoma therapeutics market size has grown rapidly in recent years. It will grow from $3.67 billion in 2023 to $4.1 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The growth observed in the historical period can be attributed to a shift in treatment guidelines, heightened awareness and early detection efforts, regulatory approvals, and participation in clinical trials, as well as advancements in surgical techniques.

The melanoma therapeutics market size is expected to see rapid growth in the next few years. It will grow to $6.16 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The anticipated growth in the forecast period can be attributed to the emergence of new treatment modalities, the identification of biomarkers, regulatory support for innovation, advancements in personalized medicine, and enhancements in immunotherapy. Significant trends expected in this forecast period include the evolution of treatment guidelines, the integration of telemedicine in oncology, increased focus on patient advocacy and awareness, ongoing biomarker research, and the development of combination therapies.

The anticipated increase in melanoma cases is poised to drive the growth of the melanoma therapeutics market in the foreseeable future. Melanoma, a type of skin cancer originating from melanocytes, is treated with therapies and drugs specifically designed for melanoma patients to mitigate the effects of the disease. The rising incidence of melanoma is expected to contribute to increased sales of melanoma therapeutics. As of May 2022, the World Health Organization projected approximately 325,000 new cases and 57,000 deaths globally due to melanoma in 2020. IARC (International Agency for Research on Cancer) scientists further anticipate a more than 50% increase in cutaneous melanoma cases to over 500,000 annually and a more than two-thirds increase in melanoma-related deaths to almost 100,000 annually between 2020 and 2040. Consequently, the growing incidence of melanoma is a significant factor propelling the growth of the melanoma therapeutics market.

The rise in the aging population is expected to drive the growth of the melanoma therapeutics market in the coming years. An aging population, characterized by a higher proportion of individuals aged 65 and older within a population, experiences an increased prevalence of melanoma. Melanoma therapeutics play a crucial role in addressing this skin cancer, which becomes more common with advancing age. In October 2022, the World Health Organization reported that the global population aged 60 and above has increased to 1.4 billion in 2022, up from 1 billion in 2020. The number of individuals aged 60 and above is projected to double worldwide by 2050, reaching 2.1 billion. Additionally, the number of people aged 80 or older is expected to triple by 2050, reaching 426 million. Therefore, the growing aging population is a key driver for the melanoma therapeutics market.

Product innovation is a notable trend gaining momentum in the melanoma therapeutics market, with major companies focusing on developing new and innovative therapies to strengthen their market position. In January 2022, Immunocore, a UK-based biotechnology company, successfully developed KIMMTRAK (tebentafusp-tebn), receiving FDA approval for the treatment of metastatic uveal melanoma. KIMMTRAK is a groundbreaking bispecific protein with anti-CD3 immune-effector activity linked to a soluble T cell receptor, demonstrating an overall survival of nearly 22 months in a successful phase 3 clinical trial. This represents the first compound created using Immunocore's ImmTAC technology platform, redirecting and activating T lymphocytes to identify and eliminate tumor cells.

Major companies in the melanoma therapeutics market are introducing innovative products such as Opdualag to enhance their market profitability. Opdualag, a medication for the treatment of melanoma that has spread or cannot be surgically removed, was approved by the FDA in March 2022. Developed by Bristol Myers Squibb, Opdualag is a breakthrough combination therapy targeting both PD-1 and LAG-3, improving efficacy and tolerability compared to current immunotherapies. This provides a novel treatment option for advanced melanoma patients, enhancing the effectiveness of existing immunotherapies without significantly increasing side effects.

In April 2022, EMZ Partners, a Germany-based investment firm, acquired a majority stake in FotoFinder Systems GmbH for an undisclosed amount. This strategic partnership is expected to enable FotoFinder Systems GmbH to expand its product offerings and reach new markets. FotoFinder Systems GmbH, based in Germany, provides skin visualization equipment used in melanoma therapeutics.

Major companies operating in the melanoma therapeutics market report are AstraZeneca plc, Bristol-Myers Squibb Co., Eli Lilly and Company, Merck & Co. Inc., Novartis AG, Hoffmann-La Roche AG, Sanofi S.A., AB Science S.A, Amgen Inc., Daiichi Sankyo Company Limited, F. Hoffman-La Roche Ltd., Pfizer Inc., GlaxoSmithKline PLC, Bayer AG, AbbVie Inc., Johnson & Johnson Private Limited, The Bristol-Myers Squibb Company, Nektar Therapeutics, Immutep Ltd., Partner Therapeutics lnc., Idera Pharmaceuticals Inc., Oncolys BioPharma Inc., Iovance Biotherapeutics lnc., AIM ImmunoTech Inc., Infinity Pharmaceuticals lnc., Spring Bank Pharmaceuticals lnc., Incyte Corporation, Sun Pharmaceutical Industries Ltd., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Eisai Co.Ltd., Seattle Genetics Inc., Regeneron Pharmaceuticals Inc., Bio-Rad Laboratories Inc., Illumina Inc., Myriad Genetics Inc.

North America was the largest region in the melanoma therapeutics market in 2023. The regions covered in the melanoma therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the melanoma therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The melanoma therapeutics market includes revenues earned by entities by providing stereotactic radiosurgery, stereotactic ablative radiation therapy, intralesional therapy, and palliative therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Melanoma Therapeutics Market Characteristics

3. Melanoma Therapeutics Market Trends And Strategies

4. Melanoma Therapeutics Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Melanoma Therapeutics Market Size and Growth

  • 5.1. Global Melanoma Therapeutics Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Melanoma Therapeutics Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Melanoma Therapeutics Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Melanoma Therapeutics Market Segmentation

  • 6.1. Global Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Monoclonal Antibodies
  • Small Molecule Inhibitors
  • Other Drug Types
  • 6.2. Global Melanoma Therapeutics Market, Segmentation By Therapy:, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Surgery
  • Radiation Therapy
  • Immunotherapy
  • Targeted Therapy
  • Chemotherapy
  • 6.3. Global Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Oral
  • Injectable
  • 6.4. Global Melanoma Therapeutics Market, Segmentation By Cancer Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Superficial Spreading Melanoma
  • Nodular Melanoma
  • Lentigno Maligna Melanoma
  • Acral Lentiginous Melanoma
  • Amelanotic Melanoma
  • Other Cancer Types
  • 6.5. Global Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Dermatoscopy
  • Entinel Lymph Node Biopsy
  • Blood Test
  • X-ray
  • Ultrasound
  • CT Scan

7. Melanoma Therapeutics Market Regional And Country Analysis

  • 7.1. Global Melanoma Therapeutics Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Melanoma Therapeutics Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Melanoma Therapeutics Market

  • 8.1. Asia-Pacific Melanoma Therapeutics Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Melanoma Therapeutics Market

  • 9.1. China Melanoma Therapeutics Market Overview
  • 9.2. China Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Melanoma Therapeutics Market

  • 10.1. India Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Melanoma Therapeutics Market

  • 11.1. Japan Melanoma Therapeutics Market Overview
  • 11.2. Japan Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Melanoma Therapeutics Market

  • 12.1. Australia Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Melanoma Therapeutics Market

  • 13.1. Indonesia Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Melanoma Therapeutics Market

  • 14.1. South Korea Melanoma Therapeutics Market Overview
  • 14.2. South Korea Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Melanoma Therapeutics Market

  • 15.1. Western Europe Melanoma Therapeutics Market Overview
  • 15.2. Western Europe Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Melanoma Therapeutics Market

  • 16.1. UK Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Melanoma Therapeutics Market

  • 17.1. Germany Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Melanoma Therapeutics Market

  • 18.1. France Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Melanoma Therapeutics Market

  • 19.1. Italy Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Melanoma Therapeutics Market

  • 20.1. Spain Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Melanoma Therapeutics Market

  • 21.1. Eastern Europe Melanoma Therapeutics Market Overview
  • 21.2. Eastern Europe Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Melanoma Therapeutics Market

  • 22.1. Russia Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Melanoma Therapeutics Market

  • 23.1. North America Melanoma Therapeutics Market Overview
  • 23.2. North America Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Melanoma Therapeutics Market

  • 24.1. USA Melanoma Therapeutics Market Overview
  • 24.2. USA Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Melanoma Therapeutics Market

  • 25.1. Canada Melanoma Therapeutics Market Overview
  • 25.2. Canada Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Melanoma Therapeutics Market

  • 26.1. South America Melanoma Therapeutics Market Overview
  • 26.2. South America Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Melanoma Therapeutics Market

  • 27.1. Brazil Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Melanoma Therapeutics Market

  • 28.1. Middle East Melanoma Therapeutics Market Overview
  • 28.2. Middle East Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Melanoma Therapeutics Market

  • 29.1. Africa Melanoma Therapeutics Market Overview
  • 29.2. Africa Melanoma Therapeutics Market, Segmentation By Drug Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Melanoma Therapeutics Market, Segmentation By Route of administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Melanoma Therapeutics Market, Segmentation By Diagnosis, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Melanoma Therapeutics Market Competitive Landscape And Company Profiles

  • 30.1. Melanoma Therapeutics Market Competitive Landscape
  • 30.2. Melanoma Therapeutics Market Company Profiles
    • 30.2.1. AstraZeneca plc
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Bristol-Myers Squibb Co.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Eli Lilly and Company
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co. Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Novartis AG
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Melanoma Therapeutics Market Competitive Benchmarking

32. Global Melanoma Therapeutics Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Melanoma Therapeutics Market

34. Melanoma Therapeutics Market Future Outlook and Potential Analysis

  • 34.1 Melanoma Therapeutics Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Melanoma Therapeutics Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Melanoma Therapeutics Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer